Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy notice measurable weight loss within the first four to eight weeks, though the pace picks up considerably as the dose increases over the following months. Clinical trial data published in the STEP 1 study in the New England Journal of Medicine reported an average reduction of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose. Results vary between individuals — a prescriber, not a general estimate, is the right guide for your situation — and because Wegovy is a prescription-only medicine, a clinical assessment always comes first.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The opening pen, at 0.25mg, is designed to let your body settle into the medicine. Nausea, mild indigestion and loose stools are common at this stage and tend to ease within a week or two. Weight loss in this phase is usually modest (typically one to two kilograms) because the dose is deliberately low. Think of it less as a treatment phase and more as a runway. Your prescriber will move you to 0.5mg after roughly four weeks, and many people find the first noticeable change in appetite comes around this point: portions that used to feel normal suddenly feel like too much.
The NHS medicines page for semaglutide explains what to expect during the titration period and which side effects are common at each stage. Keeping Wegovy in the fridge door alongside everyday items is a practical way to build the once-weekly injection into a routine without it feeling clinical, though the exact storage window is set out in the Patient Information Leaflet rather than here.
Practically: don't measure progress against friends at this stage. The 0.25mg and 0.5mg doses exist for tolerability, not for maximum effect.
As the dose climbs through 1.0mg and 1.7mg, appetite suppression deepens and weight loss typically accelerates. For many people this is the most visible phase. Data from the STEP 1 trial showed that by the six-month mark, participants had lost roughly half of the total weight they would eventually lose over 68 weeks. That front-loading effect is worth knowing: it can make the later months feel slower even when steady progress continues.
The mechanics behind this (Wegovy activates GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing hunger signals) mean the medicine is doing more at higher doses. Not everyone reaches 2.4mg; some people maintain excellent results at 1.7mg and stay there on their prescriber's recommendation. If you are curious about the rate of loss at different dose levels, more detail is covered there.
Protein intake, hydration and some resistance activity all help preserve muscle during this phase. A dietitian or your prescriber can advise on the specifics for your circumstances.
Once you reach 2.4mg, average loss in the STEP 1 trial continued but at a slower rate. A plateau (where weight stays roughly flat for several weeks) is normal and does not mean the medicine has stopped working. The body's energy-compensation systems push back as weight falls, which is a biological response, not a willpower problem. If you want to understand how long it typically takes to lose weight on Wegovy, the answer varies by individual but most people reach their lowest weight somewhere between months twelve and sixteen on the full dose.
The NICE appraisal of semaglutide for weight management (NICE TA875) notes that if less than 5% of starting weight has been lost after six months at the maintenance dose, continuing treatment should be reviewed with a clinician. That figure gives a useful reference point for conversations with your prescriber about whether the medicine is working as expected for you.
It is also worth understanding the broader timeline for how Wegovy takes effect, some people see appetite changes before the scales move, which is a normal part of the process.
Two people can take the same dose for the same length of time and lose quite different amounts of weight. Starting BMI matters: people with a higher starting weight often see larger absolute losses but not always a higher percentage. Genetics, gut microbiome, sleep quality, stress and underlying metabolic conditions all play a role. This is not an excuse or a caveat, it is the honest picture the trial data supports.
For those thinking about semaglutide's broader weight-loss timeline (across both Wegovy and the diabetes medicines that share the same active ingredient) the pattern is similar, but the licensed indication and dosing are different, which is why those comparisons need to be made carefully. If you want to understand how long you may need to take Wegovy to see meaningful weight loss, that is covered in more detail alongside guidance on what shapes the duration for different people. If you are still weighing up your options, an overview of the treatment choices available in the UK may help you come to the conversation with your prescriber better informed.
A note on cost: private Wegovy treatment is priced per pen and varies by dose and provider. If you are researching the cost of Wegovy through a private pharmacy, it is worth understanding what a quoted price does and does not include. Speed of results is not something a lower price buys; clinical oversight is.
When you are ready to explore whether Wegovy could be right for you, speak to our prescribers through a free consultation. A GPhC-registered clinician reviews every assessment the same day, and a conversation about your timeline and expectations is part of that process.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.